Navigation

Asthma (uncontrolled) - omalizumab

Omalizumab for severe persistent allergic asthma

Status: History
Expected date of issue: TBC
Process: STA
Topic area:
  • Respiratory
 

NICE project team

Executive Lead: Gillian Leng
Technical Lead: Ebenezer Tetteh
Communications manager: Kristin O'Leary
Project manager: Chris Feinmann
Assessment Group / Evidence Review Group: Southampton Health Technology Assessment Centre (SHTAC), University of Southampton
Top


 

Provisional schedule

Closing date for invited submissions / evidence submission: 31 January 2007
Final scope published: November 2006
1st appraisal committee meeting: 16 May 2007
2nd appraisal committee meeting TBC
Top


 

Consultees and commentators

Consultees Commentators (no right of appeal)

Manufacturers / Sponsors

  • Novartis Pharmaceuticals UK Ltd (omalizumab)

Patient / Carer Groups

  • Action Against Allergy
  • Allergy UK
  • Asthma UK
  • British Lung Foundation
  • Specialised Healthcare Alliance

Professional Groups

  • British Society for Allergy & Clinical Immunology (BSCAI)
  • British Paediatric Respiratory Society
  • British Thoracic Society
  • Cochrane Airways Group
  • General Practice Airways Group (GPIAG)
  • Royal College of General Practitioners
  • Royal College of Nursing
  • Royal College of Paediatrics and Child Health
  • Royal College of Physicians
  • Royal Pharmaceutical Society of Great Britain
  • UK Clinical Pharmacy Association (UKCPA)

Others

  • Department of Health
  • North Peterborough PCT
  • Southampton City PCT
  • Welsh Assembly Government

General

  • Board of Community Health Councils in Wales
  • British National Formulary
  • Department of Health, Social Services and Public Safety for Northern Ireland
  • Medicines and Healthcare products Regulatory Agency (MHRA)
  • NHS Confederation
  • NHS Purchasing and Supplies Agency
  • NHS Quality Improvement Scotland
  • Scottish Medicines Consortium

Comparator Manufacturers

  • None

Evidence Review Groups

  • National Coordinating Centre for Health Technology Assessment
  • Southampton Health Technology Assessment  Centre, University of Southampton (SHTAC)

Associated Guideline Groups

  • None

Associated Public Health Groups

  • None

Research Groups

  • Asthma, Allergy and Inflammation Research Trust (AAIR)
  • Education for Health
  • Midlands Asthma and Allergy Research Association (MAARA)
  • National Society for Research into Allergy (NSRA)

Top


 

Project history

Date Update
12 March 2004 Date of information meeting for consultees stated and Alec Miners appointed Technical Lead.
19 August 2004 This topic was originally referred to NICE as part of the 8th wave, but due to timetabling constraints will now be considered along with 10th wave topics.
25 January 2005 Project manager updated.
7 February 2005 Appraisal suspended.
29 November 2005 Expected date of issue added, assessment group changed and dates for consultation, consultee meeting and appraisal committee meetings added.
25 August 2006 This topic was transferred to the Single technology appraisal (STA) process as part of the Institute's 12th wave work programme.
20 March 2007 Project team updated.
3 April 2007 Project team and schedule updated.
Top


 

Key documents

This page was last updated: 30 March 2010

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.